The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori

This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole versus Esomeprazole-containing Bismuth quadruple therapy for eradication of Helicobacter pylori in China.

NCT Number	NCT07606833
Lead Sponsor	Xuanzhu Biopharmaceutical Co., Ltd.
Conditions	HELICOBACTER PYLORI INFECTIONS
Enrollment	556 participants
Start Date	2026-06-10
Primary Completion	2027-02-19 (estimated)
Study Completion	2027-03-18 (estimated)
Updated on ClinicalTrials.gov	2026-05-26